22nd Century Group Inc (NYSEAMERICAN:XXII) has appointed Juan Sanchez Tamburrino, Ph.D., as the firm’s VP of R&D. Dr. Tamburrino was formerly the head of the Plant Biotechnology Segment of British American Tobacco.

The details

In 2009, Dr. Tamburrino was engaged as the head of the Plant Biotechnology segment of British American Tobacco in Cambridge, England. In this role, he was responsible for biotechnology plan related to tobacco leaf. He advanced molecular breeding and GMO programs at BAT and advanced the world’s most comprehensive tobacco genome sequence. Dr. Tamburrino’s experience comprises extensive work in toxicant reduction plans for tobacco, and gene mutation methods and technologies for agronomic trait improvements for different commercial crops. He directed BAT’s global intellectual property plans for leaf tobacco.

At 22nd Century, Dr. Tamburrino will serve as VP of Research and Development after the retirement of Dr. Michael Moynihan. As it is known, Dr. Moynihan has been a key member of the company’s management team for over 10 years and was responsible for looking after the advancement of the nicotine technology that is the foundation for company’s Very Low Nicotine as well as High Nicotine tobaccos.

Having directed the firm’s regulatory affairs initiatives, research and development group, aggressive growth and plant breeding programs of company’s intellectual property portfolio, Dr. Moynihan’s efforts have been key in establishing company as a pioneer in tobacco harm reduction. Post his retirement, Dr. Moynihan will continue to serve as a consultant working on company’s proprietary tobaccos for global markets and on other special assignments.

Henry Sicignano, III, the CEO and President of 22nd Century, expressed that not only did Mike Moynihan lead the advancement of what is arguably the most thrilling Modified Risk Tobacco Product candidate, he also through his extensive associations in the scientific community led them to Dr. Tamburrino. Moynihan has been an instrumental part of 22nd Century team; though they will miss him, he is extremely delighted that Moynihan will continue to support the firm’s vital work, even as he cherishes his well-earned retirement.